Caveolin-1 in sarcomas: Friend or foe?

Oncotarget

Volumn 2, Issue 4, 2011, Pages 305-312

  Sáinz Jaspeado, Miguel ^a   Martin Liberal, Juan ^a   Lagares Tena, Laura ^a   Mateo Lozano, Silvia ^b   del Muro, Xavier Garcia ^a   Tirado, Oscar M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Caveolin 1; Oncogene; Sarcomas; Tumor suppressor

Indexed keywords

CAVEOLIN 1; CAVEOLIN 2; CAVEOLIN 3; TUMOR MARKER;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CARCINOGENICITY; DISEASE ASSOCIATION; DOWN REGULATION; EWING SARCOMA; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LONG TERM SURVIVAL; MESENCHYME CELL; NONHUMAN; ONCOGENE; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; BIOLOGICAL MODEL; BONE TUMOR; DISEASE COURSE; GENETICS; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PHYSIOLOGY; REVIEW; SOFT TISSUE TUMOR;

ANIMALS; BONE NEOPLASMS; CAVEOLIN 1; DISEASE PROGRESSION; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; SARCOMA; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 79961122172     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.255     Document Type: Article

References (54)

1. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Washington, DC: IARC Press. 2002; 120-2.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
3. Ray-Coquard I, Thiesse P, Ranchère-Vince D, Chauvin F, Bobin JY, Sunyach MP, Carret JP, Mongodin B, Marec-Bérard P, Philip T, Blay JY. Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. Ann Oncol. 2004; 15: 307-15.
4. de Alava E. Molecular pathology in sarcomas. Clin Transl Oncol 2007; 9: 130-144
5. Ordóñez JL, Osuna D, García-Domínguez DJ, Amaral AT, Otero-Motta AP, Mackintosh C, Sevillano MV, Barbado MV, Hernández T, de Alava E. The clinical relevance of molecular genetics in soft tissue sarcomas. Adv Anat Pathol. 2010; 17: 162-81.
6. Jain S, Xu R, Prieto VG, Lee P. Molecular classification of soft tissue sarcomas and its clinical applications. Int J Clin Exp Pathol. 2010 Apr 23; 3: 416-28.
7. Parton RG. Caveolae and caveolins. Curr Opin Cell Biol. 1996; 8: 542-548.
8. Engelman JA, Zhang XL, Galbiati F, Lisanti MP. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, -2, and -3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Lett. 1998; 429: 330-336.
9. Parolini I, Sargiacomo M, Galbiati F, Rizzo G, Grignani F, Engelman JA, Okamoto T, Ikezu T, Sherer PE, Mora R, Rodriguez-Boulan E, Peschle C, Lisanti MP. Expression of caveolin-1 is required for the transport of caveolin-1 to the plasma membrane. Retention of caveolin-2 at the level of the golgi complex. J Biol Chem. 1999; 274: 25718-25725.
10. Way M, Parton RG. M-caveolin, a muscle-specific caveolin-related protein. FEBS Lett. 1996; 378: 108-112.
11. Tang Z, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF, Lisanti MP. Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem. 1996; 271: 2255-2261.
12. Bastiano M, Parton RG. Caveolae at a glance. J Cell Sci. 2010; 123: 3831-3836.
13. Burgermeister E, Liscovitch M, Röcken C, Schmid RM, Ebert MP. Caveats of caveolin-1 in cancer progression. Cancer Lett. 2008; 268: 187-201.
14. Quest AF, Gitierrez-Pajares JL, Torres VA. Caveolin-1: an ambiguous partner in cell signalling and cancer. J Cell Mol Med. 2008; 12: 1130-1150.
15. Wiechen K, Sers C, Agoulnik A, Arlt K, Dietel M, Schlag PM, Scheider U. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am J Pathol. 2001; 158: 833-839.
16. Kim E-J, Sohn JH, Kim M-K, Chae SW, Lee HS, Cho EY, Kim WH. The loss of expression of caveolin-1 in gastrointestinal stromal tumors. Korean J Pathol. 2005; 39: 338-344.
17. Bayer-Garner I, Morgan M, Smoller BR. Caveolin expression is common among bening and malignant smooth muscle and adipocyte neoplasms. Mod Pathol. 2002; 15: 1-5.
18. Zucman J, Delattre O, Desmaze C, Plougastel B, Joubert I, Melot T, Peter M, De Jong P, Roulleau G, Aurias A, Thomas G. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer. 1992; 5: 271-277.
19. Mateo-Lozano S, Tirado OM, Notario V. Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene. 2003; 22:9282-9287.
20. Kovar H, Ban J, Pospisilova S. Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin Cancer Biol. 2003; 13: 275-81.
21. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005; 65: 8984-8992.
22. Mateo-Lozano S, Gokhale PC, Soldatenkov VA, Dritschilo A, Tirado OM, Notario V. Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma. Clin Cancer Res. 2006; 12: 6781-6790.
23. Toub N, Bertrand JR, Malvy C, Fattal E, Couvreur P. Antisense oligonucleotide nanocapsules efficiently inhibit EWS-Fli1 expression in a Ewing's sarcoma model. Oligonucleotides. 2006; 16: 158-168.
24. Tirado OM, Mateo-Lozano S, Villar J, Dettin LE, Llort A, Gallego S, Ban J, Kovar H, Notario V. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells. Cancer Res. 2006; 66: 9937-9947.
25. Llombart-Bosch A, Machado I, Navarro S, Bertoni F, Bacchini P, Alberghini M, Karzeladze A, Savelov N, Petrov S, Alvarado-Cabrero I, Mihaila D, Terrier P, Lopez-Guerrero JA, Picci P. Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Wirchows Arch. 2009; 455: 397-411.
26. Tirado OM, MacCarthy CM, Fatima N, Villar J, Mateo-Lozano S, Notario V. Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing's sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer. 2010; 126: 426-436.
27. Sáinz-Jaspeado M, Lagares-Tena L, Lasheras J, Navid F, Rodriguez-Galindo C, Mateo-Lozano S, Notario V, Sanjuan X, Garcia del Muro X, Fabra A, Tirado OM. Caveolin-1 modulates the ability of Ewing's sarcoma to metastasize. Mol Cancer Res 2010; 8: 1489-1500.
28. Sengupta A, Mateo-Lozano S, Tirado OM, Notario V. Auto-stimulatory action of secreted caveolin-1 on the proliferation of Ewing's sarcoma cells. Int J Oncol. 2011; 38: 1259-1265.
29. Lau CC. Molecular classification of osteosarcoma. Cancer Treat Res. 2009; 152: 459-465.
30. Cantiani L, Manara MC, Zucchini C, De Danctis P, Zuntini M, Valvassori L, Serra M, Olivero M, Di Renzo MF, Colombo MP, Picci P, Scotlandi K. Caveolin-1 reduces osteosarcoma metastases by inhibiting c-Src activity and met signalling. Cancer Res. 2007; 67: 7675-7685.
31. Mayordomo E, Machado I, Giner F, Kresse SH, Myklebost O, Carda C, Navarro S, Llombart-Bosch A. A tissue microarray study of osteosarcoma: histopathologic and immunohistochemical validation of xenotransplanted tumors as preclinical models. Appl Immunohistochem Mol Morphol. 2010; 18: 453-461.
32. Huh WW, Skapek SX. Childhood rhabdomyosarcoma: new insight on biology and treatment. Curr Oncol Rep. 2010; 12: 402-410.
33. De Giovanni C, Landuzzi L, Nicoletti G, Lollini PL, Nanni P. Molecular and cellular biology of rhabdomyosarcoma. Future Oncol. 2009; 5: 1449-1475.
34. Galli N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ 3rd, Emanuel BS, Rovera G, Barr FG. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet. 1993; 5: 230-235.
35. Davis RJ, D'Cruz CM, Lovell MA, Biegel JA, Barr FG. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res. 1994; 54: 2869-2872.
36. Song KS, Scherer PE, Tang Z, Okamoto T, Li S, Chafel M, Chu C, Kohtz DS, Lisanti MP. Expression of caveolin-3 in skeletal, cardiac, and smoothmuscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem. 1996; 271: 15160-15165.
37. Fine SW, Lisanti MP, Argani P, Li M. Caveolin-3 is a sensitive and specific marker for rhabdomyosarcoma. Appl Immunohistochem Mol Morphol. 2005; 13: 231-236.
38. Rossi S, Poliani PL, Cominelli M, Bozzato A, Vescovi R, Monti E, Fanzani A. Caveolin 1 is a marker of poor differentiation in rhabdomyosarcoma. Eur J Cancer. 2011; 47: 761-772.
39. Razani B, Zhang XL, Bitzer M, von Gersdorff G, Böttinger EP, Lisanti MP. Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem. 2001; 276: 6727.
40. Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Béliveau R. Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell. 2003; 14: 334-347.
41. Newcomb LF, Mastick CC. Src family kinase-dependent phosphorylation of a 29-kDa caveolin-associated protein. Biochem Biophys Res Commun. 2002; 290: 1447-1453.
42. Grande-García A, Echarri A, de Rooij J, Alderson NB, Waterman-Storer CM, Valdivieso JM, del Pozo MA. Caveolin-1 regulates cell polarization and directional migration through Src kinase and Rho GTPases. J Cell Biol. 2007; 177: 683-694.
43. Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 1997; 272: 30429-30438.
44. Lajoie P, Kojic LD, Nim S, Li L, Dennis JW, Nabi IR. Lattices, rafts, and scaffolds: domain regulation of receptor signaling at the plasma membrane. J Cell Biol. 2009; 185: 381-385.
45. Bhatnagar A, Sheffler DJ, Kroeze WK, Compton-Toth B, Roth BL. Caveolin-1 interacts with 5-HT2A serotonin receptors and profoundly modulates the signaling of selected Galphaq-coupled protein receptors. J Biol Chem. 2004; 279: 34614-34623.
46. Nabi IR. Cavin fever: regulating caveolae. Nat Cell Biol. 2009; 11: 789-791.
47. Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin-1 re-expression in human breast cancer cells. Oncogene. 1998; 16: 1391-1397.
48. Han F, Zhu HG. Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells. J Surg Res. 2010; 159: 443-450.
49. Sloan EK, Stanley KL, Anderson RL. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene. 2004; 23: 7893-7897.
50. Gratton JP, Lin MI, Yu J, Weiss ED, Jiang ZL, Fairchild TA, Iwakiri Y, Groszmann R, Claffey KP, Cheng YC, Sessa WC. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003; 4: 31-39.
51. Tahir SA, Park S, Thompson TC. Caveolin-1 regulates VEGF-stimulated angiogenic activities in prostate and endothelial cells. Cancer Biol Ther. 2009; 8: 2286-2296.
52. Felicetti F, Parolini I, Bottero L, Fecchi K, Errico MC, Raggi C, Biffoni M, Spadaro F, Lisanti MP, Sargiacomo M, Carè A. Caveolin-1 tumor-promoting role in human melanoma. Int J Cancer. 2009; 125: 1514-1522.
53. Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, Anderson KC. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004; 64: 7500-7506.
54. Wu H, Jiang H, Lu D, Xiong Y, Qu C, Zhou D, Mahmood A, Chopp M. Effet of simvastatin on glioma cell proliferation, migration, and apoptosis. Neurosurgery. 2009; 65: 1087-1096.